D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment

Yalcin A. D., Celik B., GÜMÜŞLÜ S.

EXPERT OPINION ON BIOLOGICAL THERAPY, cilt.14, sa.3, ss.283-286, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 3
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1517/14712598.2014.875525
  • Dergi Adı: EXPERT OPINION ON BIOLOGICAL THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.283-286
  • Anahtar Kelimeler: anti-immunoglobulin E, antithrombin III, chronic urticaria, d-dimer, factor V Leiden and prothrombin G20210A mutation, omalizumab, protein C, severe persistent allergic asthma
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: D-dimer (DD), a fibrin degradation product formed during the lysis of a thrombus, is also detected in high levels in patients with active chronic urticaria (CU). Severe persistent allergic asthma (SPA) is associated with a procoagulant state in the bronchoalveolar space, further aggravated by impaired local activities of the anticoagulant protein C/protein S, antithrombin III system and fibrinolysis. This was demonstrated as massive fibrin depositions found in the alveoli of a SPA patient who died from a SPA attack and who did not respond to treatment.